Page last updated: 2024-10-16

betaine and Recrudescence

betaine has been researched along with Recrudescence in 3 studies

glycine betaine : The amino acid betaine derived from glycine.

Research Excerpts

ExcerptRelevanceReference
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke."8.02Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021)
"We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke."4.02Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021)
"Malignant hypertension was diagnosed."1.40Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. ( Benoist, JF; Cornec-Le Gall, E; De Parscau, L; Delmas, Y; Doucet, L; Fremeaux-Bacchi, V; Le Meur, Y; Ogier, H, 2014)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Zhong, C1
Miao, M1
Che, B1
Du, J1
Wang, A1
Peng, H1
Bu, X1
Zhang, J1
Ju, Z1
Xu, T1
He, J1
Zhang, Y1
Cornec-Le Gall, E1
Delmas, Y1
De Parscau, L1
Doucet, L1
Ogier, H1
Benoist, JF1
Fremeaux-Bacchi, V1
Le Meur, Y1
Herlofson, BB1
Barkvoll, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072]4,071 participants (Actual)Interventional2009-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Usual Care502
Active Antihypertensive Treatment500

A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks

Interventionparticipants (Number)
Usual Care681
Active Antihypertensive Treatment683

Cognitive Function (Montreal Cognitive Assessment)

Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months

InterventionMoCA score (Median)
Usual Care22
Active Antihypertensive Treatment22

Cognitive Function (the Mini-Mental State Examination)

Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months

InterventionMMSE score (Median)
Usual Care26
Active Antihypertensive Treatment26

Long-term Neurological and Functional Status

Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months

InterventionScore on modified Rankin scale (Median)
Usual Care1.0
Active Antihypertensive Treatment1.0

Mortality

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Active Antihypertensive Treatment68
Usual Care54

Other Vascular Events

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Usual Care59
Active Antihypertensive Treatment48

Recurrent Stroke

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months

Interventionparticipants (Number)
Active Antihypertensive Treatment28
Usual Care43

Trials

1 trial available for betaine and Recrudescence

ArticleYear
The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers.
    Acta odontologica Scandinavica, 1996, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Aged; Betaine; Child; Cross-Over Studies; Detergents; Double-Blind Method; Female

1996

Other Studies

2 other studies available for betaine and Recrudescence

ArticleYear
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
    The American journal of clinical nutrition, 2021, 10-04, Volume: 114, Issue:4

    Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag

2021
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 63, Issue:1

    Topics: Adult; Amino Acid Metabolism, Inborn Errors; Antibodies, Monoclonal, Humanized; Betaine; Biopsy; Car

2014